Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Oncolytics Biotech Inc
Oncolytics Biotech Inc
Activities:
Manufacturing
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Media
Oncolytics Biotech collaborates with SOLTI
The clinical collaboration will see some patients receive an intravenously delivered immuno-oncolytic virus, REOLYSIN, developed by the biotech company
Pharmaceutical
Oncolytics collaborates with Roche
The biotechnology company currently developing an intravenously delivered immuno-oncolytic virus has announced it has entered into a master clinical supply agreement
Ingredients
Oncolytics Biotech and SAFC enter into commercial supply agreement
Significant step forward in commercialising Oncolytics’ proprietary formulation of the human reovirus
Subscribe now